NCT06304194 Molecular Characterizazion and Biological Samples Centralisation of Patients Affected by Oncoematolofic Pathology
| NCT ID | NCT06304194 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Meyer Children's Hospital IRCCS |
| Condition | Oncologic Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 340 participants |
| Start Date | 2023-07-05 |
| Primary Completion | 2027-07-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 340 participants in total. It began in 2023-07-05 with a primary completion date of 2027-07-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Currently, the molecular characterization of onco-hematological, onco-immunological and hematological diseases, at onset or in relapse, of patients with suspected diagnosis afferent to the CROP centers, is done through centralization of biological samples at reference laboratories outside the Tuscany Region. In order to preserve the wealth of clinical and biological data and use it for the benefit of present and future patients treated at the CROP centers, it is useful to evaluate the feasibility of centralization and molecular typing of mutations present in tumor tissue at the IRCCS AOU Meyer Oncohematology Laboratories and subsequently the analysis of clinical data from patients with diseases not under study to lay the foundations of a translational database that can then be associated with a biobank in the future. This will enable a targeted contribution to pediatric oncohematology research, investing in possible targeted therapies with those patient subgroups that benefit from personalized disease assessment in mind. The goal of the project is to improve the regional infrastructure dedicated to organized data collection and management of biological samples in adequate time resulting in better and more comprehensive data collection.
Eligibility Criteria
Inclusion Criteria: * Diagnostic suspicion of oncologic, hematologic or onco-immunologic disease * Suspected recurrence of oncological, onco-hematological, hematological or onco -immunological disease * Availability of biological material * Signature of informed consent * Age between 0 and 30 years Exclusion Criteria: * Failure to sign the consent * Insufficiency of biological material for analysis * Patients with HIV, HCV and HBV seropositivity (HBSAg) due to biohazard and bias related to patients' immunological status that could influence gene expression and tumor behavior.
Contact & Investigator
Marinella Veltroni
PRINCIPAL INVESTIGATOR
Meyer Children's Hospital IRCCS
Frequently Asked Questions
Who can join the NCT06304194 clinical trial?
This trial is open to participants of all sexes, aged 0 Years or older, up to 30 Years, studying Oncologic Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06304194 currently recruiting?
Yes, NCT06304194 is actively recruiting participants. Contact the research team at marinella.veltroni@meyer.it for enrollment information.
Where is the NCT06304194 trial being conducted?
This trial is being conducted at Florence, Italy, Pisa, Italy, Siena, Italy.
Who is sponsoring the NCT06304194 clinical trial?
NCT06304194 is sponsored by Meyer Children's Hospital IRCCS. The principal investigator is Marinella Veltroni at Meyer Children's Hospital IRCCS. The trial plans to enroll 340 participants.